The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Combined CSF tau, p-tau181 and amyloid-β 38/40/42 for diagnosing Alzheimer’s disease
Open accessAbstract
Cerebrospinal fluid (CSF) concentrations of amyloid-beta (Abeta) 1-38, 1-40, 1-42, total-tau and phospho-tau in samples from 156 patients with Alzheimer's disease (AD) (n = 44), depressive cognitive complainers (DCC, n = 25) and various other forms of non-Alzheimer dementias (NAD, n = 87) were analyzed by electrochemiluminescence and enzyme linked immunosorbent assay, respectively. A significant decrease of CSF Abeta1-42 was the most powerful single marker for differentiation of AD from DCC, yielding accuracies of beyond 85%. Increased p-tau and the ratio Abeta1-42/Abeta1-38 yielded accuracies of beyond 80 and 85%, respectively, to discriminate AD versus NAD. Combining p-tau with Abeta1-42/Abeta1-38 resulted in a sensitivity of 94% for detection of AD and 85% specificity for excluding NAD. Decreased CSF Abeta1-42 represents a core biomarker for AD. The lack of specificity for exclusion of NAD can be most effectively compensated by the ratio Abeta1-42/Abeta1-38. The ratio Abeta1-42/Abeta1-38/p-tau powerfully discriminates AD versus NAD and fulfils the accuracy requirements for an applicable screening and differential diagnostic AD biomarker.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition, it has been shown that the levels of Aβ38, Aβ42 and the Aβ42/Aβ38 ratio in cerebral spinal fluid (CSF) can be used to distinguish AD from other dementias [32–34].”
From Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease (2020) · cites this paper as [32]
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Glenner, G. G., & Wong, C. W. (1984) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(84)80190-4 · Cited by 5,404
Frontotemporal lobar degeneration: A consensus on clinical diagnostic criteria
Neary, D., Snowden, J. S., Gustafson, L., Passant, U., Stuss, D., Black, S., Freedman, M., Kertesz, A., Robert, P. H., Albert, M., et al. (1998) · Neurology · doi:10.1212/wnl.51.6.1546 · Cited by 5,047
Román, G. C., Tatemichi, T. K., Erkinjuntti, T., Cummings, J. L., Masdeu, J. C., Garcia, J. H., Amaducci, L., Orgogozo, J.-M., Brun, A., Hofman, A., et al. (1993) · Neurology · doi:10.1212/wnl.43.2.250 · Cited by 4,921
McKeith, I. G., Galasko, D., Kosaka, K., Perry, E. K., Dickson, D. W., Hansen, L. A., Salmon, D. P., Lowe, J., Mirra, S. S., Byrne, E. J., et al. (1996) · Neurology · doi:10.1212/wnl.47.5.1113 · Cited by 3,960
The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease.
Gibb, W. R., & Lees, A. J. (1988) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.51.6.745 · Cited by 3,481
Weıntraub, S. (1990) · Archives of Neurology · doi:10.1001/archneur.1990.00530120075013 · Cited by 3,018
Gandevia, B., & Tovell, A. (1964) · PubMed · Cited by 2,069
A68: a Major Subunit of Paired Helical Filaments and Derivatized Forms of Normal Tau
Lee, V. M.-Y., Balin, B. J., Otvos, L., & Trojanowski, J. Q. (1991) · Science · doi:10.1126/science.1899488 · Cited by 1,418 · cited 1×
“The major constituent of NFT’s is tau, a microtubule-associated protein that undergoes excessive phosphorylation (phosphorylated tau, p-tau) at multiple sites (e.g. p-tau199, p-tau181 and p-tau231) and aggregates into paired helical filaments in AD (Lee et al. 1991).”
BackgroundA subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity
Weggen, S., Eriksen, J. L., Das, P., Sagi, S. A., Wang, R., Pietrzik, C. U., Findlay, K. A., Smith, T. E., Murphy, M. P., Bulter, T., et al. (2001) · Nature · doi:10.1038/35102591 · Cited by 1,388 · cited 2×
“…distributions of different Ab species are regulated within very narrow limits (Wiltfang et al. 2002; Bibl et al. 2007a; Wiltfang et al. 2007) (4) Distinct g-secretase activities may be reflected most adequately by the ratio Ab1-42/Ab1-40 Wiltfang et al. 2001) or Ab1-38/Ab1-40 (Weggen et al. 2001).”
Background
Cited by
Sorted by citations
Items 101–152 of 152
Barrado, L. G., Coart, E., & Burzykowski, T. (2016) · Biometrics · doi:10.1111/biom.12583 · Cited by 12
da Rosa, M. I., Perucchi, J. L., Medeiros, L. R., Fernandes, B. B., dos Reis, M. E. F., & Silva, B. R. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-132264 · Cited by 11
Preliminary Study for a Multicenter Study of Alzheimer's Disease Cerebrospinal Fluid Biomarkers
Park, S. A., Kim, J.-H., Kim, H. J., Kim, T. E., Kim, Y.-J., Lee, D. H., Park, J. H., Chae, W. S., Yim, S. J., Seo, S. W., et al. (2013) · Dementia and Neurocognitive Disorders · doi:10.12779/dnd.2013.12.1.1 · Cited by 10
Saleh, S. R., Abdelhady, S. A., Khattab, A. R., & El-Hadidy, W. F. (2020) · Journal of Chemical Neuroanatomy · doi:10.1016/j.jchemneu.2020.101878 · Cited by 10
Alzheimer's disease: still a perplexing problem
Chinthapalli, K. (2014) · BMJ · doi:10.1136/bmj.g4433 · Cited by 11
Effects of Probiotics on Colitis-Induced Exacerbation of Alzheimer’s Disease in AppNL-G-F Mice
Sahu, B., Johnson, L. M., Sohrabi, M., Usatii, A. A., Craig, R. M. J., Kaelberer, J. B., Chandrasekaran, S. P., Kaur, H., Nookala, S., & Combs, C. K. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411551 · Cited by 9
Chang, M., & Brainerd, C. J. (2022) · Journal of Clinical and Experimental Neuropsychology · doi:10.1080/13803395.2022.2115015 · Cited by 8
Zou, Y., Yu, S., Ma, X., Ma, C., Mao, C., Mu, D., Li, L., Gao, J., & Qiu, L. (2022) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2022.11.013 · Cited by 9
The Diagnostic Potential of Amyloidogenic Proteins
Jin, Y., Vadukul, D. M., Gialama, D., Ge, Y., Thrush, R. J., White, J. T., & Aprile, F. A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22084128 · Cited by 9
Nguyen, D. L., Okolicsanyi, R. K., & Haupt, L. M. (2024) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2024.103936 · Cited by 9
Krüger, L., Biskup, K., Schipke, C. G., Kochnowsky, B., Schneider, L., Peters, O., & Blanchard, V. (2024) · Biomolecules · doi:10.3390/biom14050512 · Cited by 9
A Common Variant in the MC1R Gene (p.V92M) is associated with Alzheimer’s Disease Risk
Tell‐Martí, G., Puig‐Butillé, J. A., Potrony, M., Plana, E., Bádenas, C., Antonell, A., Sánchez‐Valle, R., Molinuevo, J. L., Lleó, A., Alcolea, D. A., et al. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-161113 · Cited by 8
Neue diagnostische Methoden bei Demenzen
Wiltfang, J. (2015) · Der Nervenarzt · doi:10.1007/s00115-014-4177-5 · Cited by 5
Self-citationSahu, B., Nookala, S., Floden, A. M., Ambhore, N. S., Sathish, V., Klug, M. G., & Combs, C. K. (2024) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2024.07.038 · Cited by 7
Massa, F., Farotti, L., Eusebi, P., Capello, E., Dottorini, M. E., Tranfaglia, C., Bauckneht, M., Morbelli, S. D., Nobili, F. M., & Parnetti, L. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190539 · Cited by 8
Alzheimer's Disease; Mechanism, Mutations, and Applications of Nano-Medicine
Maisam, M., Khan, M. T., Lodhi, M. S., Mou, K., Liu, Z., & Wei, D. (2023) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2810258 · Cited by 7
Martins, T. S., Pelech, S., Ferreira, M., Pinho, B. B., Leandro, K., de Almeida, L. P., Breitling, B., Hansen, N., Esselmann, H., Wiltfang, J., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031584 · Cited by 6
Self-citationFronek, K., Lange, P., Spreer, A., Eiffert, H., & Nau, R. (2011) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000330912 · Cited by 6
Advances and emerging challenges in detecting Tau proteoforms for Alzheimer's disease diagnosis
Cai, Q., Miao, M., & Li, Z. (2026) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2026.118897 · Cited by 3
Diagnostic Validity Comparison Between Criteria Based on CSF Alzheimer’s Disease Biomarkers
Blanco-Cantó, M. E., Monge-Argilés, J. A., Pérez‐Cejuela, C., Badía, C., Gabaldón, L., Muñoz‐Ruiz, C., Sánchez–Payá, J., Gasparini‐Berenguer, R., & Leiva-Santana, C. (2017) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/1533317516688298 · Cited by 5
Klinisch-validierte molekulare Biomarker neurodegenerativer Demenzerkrankungen
Wiltfang, J. (2014) · Der Nervenarzt · doi:10.1007/s00115-014-4086-7 · Cited by 3
Self-citationKim, Y. H., Marcus, K., Grinberg, L. T., Goehler, H., Wiltfang, J., Stephan, C., Eisenacher, M., Hardt, T., Martens, L., Dunn, M. J., et al. (2009) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.200900100 · Cited by 3
Self-citationMehta, P. D., Patrick, B. A., Barshatzky, M., Mehta, S. P., Frackowiak, J., Mazur‐Kolecka, B., & Miller, D. L. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-142592 · Cited by 3
Teunissen, C. E., & Willemse, E. (2013) · PubMed · Cited by 3
Wiltfang, J., Trost, S., & Hampel, H.-J. (2017) · Springer eBooks · doi:10.1007/978-3-662-49295-6_59 · Cited by 3
Self-citationWabuyele, S. L., & Xu, Y. (2012) · Encyclopedia of Analytical Chemistry · doi:10.1002/9780470027318.a0506.pub2 · Cited by 3
Advances in Alzheimer's Disease Biomarkers
Li, K., Gao, Y., Liu, M., & Chen, Y. (2024) · Current Alzheimer Research · doi:10.2174/0115672050366767241223050957 · Cited by 3
The Role of Cell-Free RNA in Clinical Diagnosis and Evaluation of Cell-Free RNA Extraction Methods
Le, A. P. H., & Ha, H. (2021) · World Congress on Medical Physics and Biomedical Engineering, September 7 - 12, 2009, Munich, Germany · doi:10.1007/978-3-030-75506-5_53 · Cited by 2
Liquorbiomarker zur Frühdiagnostik der Alzheimerdemenz
Wiltfang, J. (2015) · Therapeutische Umschau · doi:10.1024/0040-5930/a000675 · Cited by 2
Self-citationDenoroy, L., & Parrot, S. (2017) · Separations · doi:10.3390/separations5010002 · Cited by 2
Clinical utility of CSF Aβ38 in Japanese research and clinical cohorts
Tsukie, T., Kasuga, K., Kikuchi, M., Ishiguro, T., Miyashita, A., Onodera, O., Iwatsubo, T., Initiative, J. A. D. N., & Ikeuchi, T. (2025) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.70125 · Cited by 1
Mohammed, H. E., Haseeb, M. E., Nasser, M., Hanen, G., Abdelkader, M., Yaser, H., Yaser, S., Samir, A., Arafeh, Y., Wagdy, M., et al. (2026) · Acta Neurologica Belgica · doi:10.1007/s13760-026-03107-8 · Cited by 1
The Value of Cerebrospinal Fluid Biomarkers for the Differential Diagnosis of Dementia
Bastard, N. L., & Engelborghs, S. (2012) · Neurodegenerative Disease Management · doi:10.2217/nmt.12.11 · Cited by 1
Comparing high and low amyloid producers in Alzheimer's disease: An in-depth analysis
Leroy, M., Aziz, A. L., Schraen‐Maschke, S., Deramecourt, V., Skrobala, E., Lecerf, S., Pasquier, F., Huin, V., Bertoux, M., & Lebouvier, T. (2025) · Revue Neurologique · doi:10.1016/j.neurol.2025.02.004 · Cited by 1
Brief Visuospatial Memory Test-Revised: Form Equivalency for Ages 80-89
Powell, J. J. (2010) · CommonKnowledge Research Repository (Pacific University Oregon)
Balasa, M. (2013) · Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona)
Klinisch-validierte molekulare Biomarker neurodegenerativer Demenzerkrankungen
Psychiatrie, K. F. (2014)
Begcevic, I. (2018) · TSpace (University of Toronto)
Wiltfang, J., Trost, S., & Hampel, H.-J. (2016) · Springer eBooks · doi:10.1007/978-3-642-45028-0_59-1
Self-citationFusion of Multimodality Features for Improved Classification of Alzheimer DiseasePreprint
Shobha, S., & Karthikeyan, B. R. (2022) · Research Square · doi:10.21203/rs.3.rs-1676817/v1
A Comprehensive Review on Alzheimer’s Disease; Pathophysiology and Treatment
Nandini, N., & Cyriac, K. S. (2024) · International Journal of Pharmaceutical Sciences Review and Research · doi:10.47583/ijpsrr.2024.v84i06.007
Skin Biomarkers of Neurodegenerative Diseases
Reilly-Jankowiak, L., Bargar, C., Bunn, D., & Chen, S. G. (2025) · Springer eBooks · doi:10.1007/978-3-031-66513-4_6
Afasias primarias progresivas. Caracterización clínica y marcadores biológicos
Navarro, S. (2013) · Tesis Doctorals en Xarxa (Consorci de Serveis Universitaris de Catalunya)
Lehmann, S., Dumurgier, J., Ayrignac, X., Marelli, C., Alcolea, D. A., Fortea, J., Thouvenot, É., Delaby, C., Hirtz, C., Vialaret, J., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13047440
Lehmann, S., Dumurgier, J., Ayrignac, X., Marelli, C., Alcolea, D. A., Fortea, J., Thouvenot, É., Delaby, C., Hirtz, C., Vialaret, J., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13047446
Lehmann, S., Dumurgier, J., Ayrignac, X., Marelli, C., Alcolea, D. A., Fortea, J., Thouvenot, É., Delaby, C., Hirtz, C., Vialaret, J., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13047443
Lehmann, S., Dumurgier, J., Ayrignac, X., Marelli, C., Alcolea, D. A., Fortea, J., Thouvenot, É., Delaby, C., Hirtz, C., Vialaret, J., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13047449
Lehmann, S., Dumurgier, J., Ayrignac, X., Marelli, C., Alcolea, D. A., Fortea, J., Thouvenot, É., Delaby, C., Hirtz, C., Vialaret, J., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13047452
Item Response Theory in the Neurodegenerative Disease Data Analysis
Wang, W. (2017) · theses.fr (ABES) · doi:10.70675/fda08f82z3032z4960z8fc3zb205890acc42
Metadata
- Authors
- Welge, V., Fiege, O., Lewczuk, P., Mollenhauer, B., Esselmann, H., Klafki, H.-W., Wolf, S., Trenkwalder, C., Otto, M., Kornhuber, J., Wiltfang, J., & Bibl, M.
- Affiliations
- University of Duisburg-Essen (DE)
- Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
- University of Göttingen (DE)
- Paracelsus Elena Klinik Kassel (DE)
- Universität Ulm (DE)
- Corresponding author
- Bibl, Mirko
- ORCID
- Venue
- Journal of Neural Transmission
- Published
- 2009-01-14
- Volume
- 116
- Issue
- 2
- Pages
- 203-212
- ISSN
- 0300-9564 (ISSN-L)
- 1435-1463
- OpenAlex
- W2041245991
- Cited by
- 152
- References
- 42
- Citations by year
- 2026: 2 · 2025: 5 · 2024: 10 · 2023: 7 · 2022: 6 · 2021: 10 · 2020: 17 · 2019: 2 · 2018: 3 · 2017: 8 · 2016: 5 · 2015: 13 · 2014: 14 · 2013: 13 · 2012: 10
- FWCI
- 7.63
- Type
- journal article
- Language
- en
- Open access
- Licence
- Locations
- Journal of Neural Transmission (publishedVersion)
- PubMed (publishedVersion)
- GRO (submittedVersion, cc-by)
- Funders
- Baden-Württemberg Stiftung
- Bundesministerium für Bildung und Forschung
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Clinical Neurology › Cerebrospinal fluid and hydrocephalus
- Keywords
- Alzheimer's disease, cerebrospinal fluid biomarkers, amyloid-beta 42, phosphorylated tau, total tau, differential diagnosis of dementia, non-Alzheimer's dementia, diagnostic accuracy, screening biomarkers
- MeSH terms
- Aged, Alzheimer Disease, Enzyme-Linked Immunosorbent Assay, Female, Humans, Luminescent Measurements, Male, Middle Aged, Phosphorylation, ROC Curve, Biomarkers, Amyloid beta-Peptides, tau Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
